Expanded Access for ATB200/AT2221 for the Treatment of IOPD

• Conditions: Pompe Disease Infantile-Onset

• Registration Number: NCT04327973
• Lead Sponsor: Amicus Therapeutics

Brief Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to ATB200/AT2221.

Detailed Description

This program is being offered on a patient by patient basis.

Study Timeline

• Study First Submitted: 2020-03-27
• Study First Submitted QC: 2020-03-27
• Study First Posted: 2020-03-31
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-15
• Last Update Posted: 2024-08-16

Recruitment & Eligibility

• Status: AVAILABLE
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Patient is male or female and 0 to < 18 years old.
2. Patient has a diagnosis of Pompe disease, based on documentation of GAA genotyping demonstrating variants associated with IOPD.
3. Patient does not currently qualify for or is unable to enroll (eg, due to location, etc) in any commercial drug-sponsored ongoing clinical trial.
4. Patient is currently being treated with an approved ERT and is declining (eg, worsening in motor function, respiratory function/parameters, cardiac function, etc) based on treating physician's clinical judgement.
5. The patient's legal guardian or representative has given informed consent (and assent when age appropriate for regional requirements) to treatment prior to administering ATB200/AT2221 in a manner consistent with all national requirements.
6. If of reproductive potential and sexually active, female subjects agree to use a highly effective method of contraception throughout the duration of the treatment and for up to 90 days after their last dose of ATB200/AT2221.

Read More

Exclusion Criteria

1. Patient has a hypersensitivity to any of the excipients in ATB200, alglucosidase alfa, or AT2221
2. Patient has a medical or any other extenuating condition or circumstance that may, in the opinion of the investigator and/or Amicus, pose an undue safety risk to the patient.
3. Concomitant use of miglitol (eg, Glyset), non-AT2221 form of miglustat (eg, Zavesca), acarbose (eg, Precose or Glucobay), voglibose (eg, Volix, Vocarb,or Volibo)

Read More

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified

Trial Locations

Locations (4)

UCSF Benioff Children's Hospital Oakland; 🇺🇸 Oakland, California, United States

UF Health Shands Hospital; 🇺🇸 Gainesville, Florida, United States

University Hospital of Padova; 🇮🇹 Padova, Italy

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan